Evidence map›Paper›PMID 37660326›Full record

ArticleEpilepsia2023

Bridged bicyclic compounds: Comprehending a novel compound class as potential anti-seizure agents.

Samantha E Stilley, Akshay S Naraine, Krishna P Yadavalli, Samantha L Maki, Elyse M Jutte, Jared M Kahn, Alexis A Surtel, Salvatore D Lepore, Ken Dawson-Scully

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Samantha E StilleyDepartment of Biology, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Akshay S NaraineDepartment of Biology, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.ORCID 0000-0001-8231-2240
Krishna P YadavalliDepartment of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Samantha L MakiDepartment of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Elyse M JutteDepartment of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Jared M KahnDepartment of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Alexis A SurtelDepartment of Biology, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Salvatore D LeporeDepartment of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Ken Dawson-ScullyDepartment of Biology, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
Florida Atlantic University · USMax Planck Florida Institute for Neuroscience · USNova Southeastern University · US

Funding

Synthesis of a Bridged Bicyclic Natural Product Using Allenyl EstersR15GM110651 · NIGMS · FLORIDA ATLANTIC UNIVERSITY · PI LEPORE, SALVATORE D · 2014 to 2020
$1.2M
NIGMS NIH HHS GM110651NIGMS NIH HHS R15 GM110651
6 · The paper itself

Abstract

objectiveIn the present study, we describe a novel class of small-molecule synthetic compounds that ameliorate seizure-like behavior, using an electroshock assay to examine seizure duration in Caenorhabditis elegans. We also examine the hypothesis that these compounds, which we have called resveramorphs (RVMs), act by an irreversible binding mechanism.

methodsOur electroshock assay examines seizure duration in C. elegans and can be used as a drug-screening platform for the identification of novel anti-seizure agents. The use of C. elegans allows for a rapid and efficient method of drug screening that may take years in other higher-order model organisms. A novel wash method, paired with our electroshock assay, allows us to discern differences in biological activity when the C. elegans are incubated in different drug solutions, to establish whether these compounds can be "washed" off.

resultsOne of the RVMs (RVM-3), reported here for the first time, was found to be potent at picomolar concentrations. Insights also provided information on the potential mechanisms of action of this compound. Covalent binding is thought to provide a strong irreversible bond because of a change in structure between two of the novel RVMs described in this work. This was also discerned through the novel wash method paired with our electroshock assay. SIGNIFICANCE: RVM-3 was evaluated using our assay and found to possess anti-seizure activity at picomolar concentrations. These insights also provide information on the potential mechanisms of action of these compounds, which may include covalent binding. This was also discerned through a novel wash method paired with our electroshock assay.

Indexed as

AnticonvulsantsCaenorhabditis elegansAnimalsDisease Models, AnimalElectroshockSeizuresAnticonvulsantsantiepileptic drugcovalent inhibitiondrug discoveryelectroshockneuropharmacology

Identifiers

PMID37660326
PMCPMC10840942
OpenAlexW4386402503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.